International Journal of Pediatrics

Presentation of Sonographic Features of Pulmonary Invasive Fungal Disease in Six Children with Leukemia

Seyed Ali Alamdaran; Hajar Heidarzadeh; Navid Zavvar; Zahra Badiee; Masoumeh Jaberi; Ali Ghasemi

Volume 9, Issue 3 , March 2021, , Pages 13203-13211

https://doi.org/10.22038/ijp.2021.52657.4172

Abstract

Background The early diagnosis of invasive fungal diseases is important because the therapeutic outcome depends on the prompt initiation of appropriate interventions. In this study, ... Read More

Effects of Nutritional variables in children with iron deficiency anemia

Ali Ghasemi; Bijan Keikhaei

Volume 2, Issue 3.1 , July 2014, , Pages 183-187

https://doi.org/10.22038/ijp.2014.2619

Abstract

Introduction: Iron deficiency (ID) is the most prevalent nutritional disorder in the world. The prevalence of iron deficiency anemia (IDA) is about 9% in toddlers, 9-11% in adolescent ... Read More

Bilateral Spontaneous Hemothorax with PNET: a case report and review

Ali Ghasemi; Bijan Keikhaee

Volume 2, Issue 3.1 , July 2014, , Pages 217-219

https://doi.org/10.22038/ijp.2014.2620

Abstract

Background: Neuroectodermal Tumors (PNET) are malignant small cells neoplasm mainly occurring in children but can occur at any age. Extensive bleeding into the pleural cavity is rare ... Read More

Hematopoietic Stem Cell Transplantation for Thalassemia

Ali Ghasemi

Volume 2, Issue 2.3 , May 2014, , Pages 23-23

https://doi.org/10.22038/ijp.2014.2672

Abstract

Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic ... Read More Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant. Stem cell transplant is the only curative approach and success is inversely correlated with the degree of iron overload and hepatic damage. Without transfusions, thalassemic patients have tremendous skeleton deformities, as well as hepatomegaly and splenomegaly due to expansion of the hematopoietic system with extramedullary hematopoiesis. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) in thalassemia has been a cornerstone in the development of HSCT. The rational basis of HSCT in thalassemia consists of substituting the thalassemic HSC bearing ineffective erythropoiesis with an allogeneic one capable of effective erythropoiesis. This cellular replacement therapy is not limited to the diseased erythropoietic component, but leads to the replacement of the entire hematopoietic system. Nevertheless, it is an efficient way to obtain a long-lasting, probably permanent, clinically effective correction of hemolytic anemia, thus avoiding transfusion requirements and associated complications . The transplantation approach for a nonmalignant disease is much different from transplantation in malignancies. In the former setting, the detrimental immunologic proprieties [GVHD] of the engrafted HSC are not balanced by an antimalignancy effect. This characteristic must be always considered in determining the risk/benefit ratio and therapeutic decision such as the kind and intensity of the conditioning regimen, GVHD prophylaxis, source of HSC, and adoptive posttransplant therapies. The Pesaro group developed a prognostic scheme to predict transplant outcome in patients younger than age 17. This prognostic scheme included three variables all related to iron burden: quality of chelation received for the entire life before transplantation; hepatomegaly; and the presence of liver fibrosis at pretransplant hepatic biopsy examination. These variables stratified patients into three groups based on them having none, or one/two, or all three of the risk factors. Overall survival and thalassemia-free survival were significantly different in the three groups: 94% and 87% in the low-risk group, 84% and 81% in the intermediate-risk group, and 70% and 58% in the high-risk group, respectively. The rate of rejection/thalassemia recurrence was much higher in thalassemic patients than in patients transplanted because of malignancies. Several factors have been invoked to explain this difference: massive pretransplant exposure to blood products, not having received any chemotherapy before transplant, expanded erythropoietic marrow, and possibly splenomegaly. Key Words: Hematopoietic, Stem cell, Thalassemi.

Autologous Stem Cell in CHF(When is more effective?) Intracoronary Administration of Autologous Bone Marrow Stem Cell in Chronic Heart Failure

Farveh Vakilian; Mahmood M. Shabestari; Ali Ghasemi; Ali Eshraghi; Hoda Madani; Hoorak Poorzand; Fereshte Ghaderi; Sara Amini; Mohamad Vejdanparast; Toktam Moghiman; Arash Gholobi; Javad Ramezani; Maryam Salehi

Volume 2, Issue 2.3 , May 2014, , Pages 26-26

https://doi.org/10.22038/ijp.2014.2675

Abstract

Introduction: We aimed at evaluating the clinical, laboratory and echocardiography effects of intracoronary administration of autologous bone marrow stem cell transplantation in different ... Read More

General Anesthesia for Lumbar Puncture and Bone Marrow Aspiration /Biopsy in Children

Ali Ghasemi

Volume 2, Issue 2.3 , May 2014, , Pages 61-61

https://doi.org/10.22038/ijp.2014.2724

Abstract

Background Multiple procedures (Lumbar puncture and bone marrow aspiration /biopsy) cause pain, stress, depression and etc for the patients and their families. Various methods ... Read More

Evaluation of Therapeutic Effects of Autologous Bone Marrow Mesenchymal Stem Cells to Prevent the Progression of Chronic Nephropathy in Renal Transplant

Ali Ghasemi; Freshteh Mamdouh; Farhad Gholami

Volume 2, Issue 2.3 , May 2014, , Pages 83-84

https://doi.org/10.22038/ijp.2014.2758

Abstract

Background Chronic allograft nephropathy(CAN) is one of the most common causes of chronic and end stage renal disease. It is defined with Mainly tubular atrophy and ... Read More Background Chronic allograft nephropathy(CAN) is one of the most common causes of chronic and end stage renal disease. It is defined with Mainly tubular atrophy and interstitial fibrosis and no evidence of any other etiology, or functional disorder that caused at least three months after transplantation . Control of risk factors (HTN,DM,HLP, …) and limiting usage of calcineurin inhibitors or replace all of them keep longer it and positive C4d nephropathy shiting to celecept or increase dose recommended . The use of mesenchymal stem cells has three thrapuitic purposes : first, the ability of these cells into the desired tissue , the induced effects on cell damage and third is regulation of immune system , which is totally new way to deal with the disease. Materials and Method :Using keywords , mesenchyma cells , renal transplantation, chronic failure Search in Google Scholar , impacts of information such as PUB MED, and magazines such KIDNEY INTERNATIONAL and research centers such as the Institute of Digestive Disease Research Center, Tehran University of embryos and one book and dissertations were used. within twelve source material has been collected and summarized. Member reconstruction methods (regeneration), which auto multipotential stem cell and tissue engineering werer used, significant results obtained. In animal models and human studies , these cells inhibit the proliferation and function of immune cells ( T and B cells and NK) and adjust the function of dendritic cells and induction of regulatory T cell activity logs. Their immunomodolatory activities are through non- specific anti- proliferation activity of contact -dependent cell - cell or secreted factors such as IDO or indolamin oxidase 2 and 3 , prostaglandin E2, HLA-G, interferon, interleukin- B1 The combination of injected antibodies and stem cells transplantation was effective, the incidence of acute rejection in the first year, fewer opportunistic infections , and renal function was significantly better in the group of stem cells. The effect of autologous cell transplantation bone marrow stem cell on renal allograft significantly improved compared to that in all cases , the use of stem cell therapy approach is effective and without danger . Transplantation of bone marrow -derived mesenchymal cells with Pioglitazone in patients with decompensated cirrhosis ( clinical trial phase I). Reducing fibrosis , or prevention of fibrosis in animal studies has been shown to possess twice CD133 cell transplantation or bone marrow-derived mononuclear cells compared with a control group of patients with decompensated liver cirrhosis in human samples is ongoing .Portal venous injection of stem cells into hepatic indices somewhat improved . Repeated cell transfusions in these patients may lead to lasting health effects . No clinical studies done on the effects of these cells in transplant rejection and treatment of fibrosis. Therapy with autologous mesenchymal stem cell for allograft rejection is safe (Safety), and available (Feasibility). Findings further benefit their immunosuppressive effects. Intravenous injection of mesenchymal stem cells can largely reduce the symptoms of graft rejection and graft survival. members can help . Transplantation of mesenchymal cells, also reduces memory fatal cells. Results:Nephropathy and chronic renal allograft rejection is a potential problem that they are facing almost 90 % of the recipient ,. The two groups of Patients have similar incidence of acute rejection and graft survivle , fewer opportunistic infections in the first year , and was significantly better renal function in stem cells DGF in patients receiving stem cell significantly decreased than control group. early half of the patients in the control group had DGFwhich occurred in the first week and Cratinin was significantly lowerin the first and second week in the case group. Injections ( one million cells per kilogram of patient weight ) of autologous mesenchymal cells derived from bone marrow was done and biopsies showed, fibrosis and atrophy of the tubules according to protocol after the link (IF / TA) was approved . Studies showed that treatment with stem cells autologous transplant rejection in renal allografts is harmless (Safety), and available (Feasibility) , and findings for the benefit of their immunosuppressive effects .Conclusions: Several clinical trial was done and are doing .Therapy with autologous stem cell for choronic allograft nephropathy is harmlesss (Safety), and available (Feasibility) , and findings confirmed for the benefit of their immunosuppressive effects Derived mesenchymal stem cells not only increasing regulatory cells ,but also reduces fatal memory cells and possible repair or reconstruction may provide with these cells. Regeneration, and repair with multi -potential stem cell or isolated mesenchymal cells from the patient's associated tissue engineering , particularly in the kidney have achieved considerable results.

International Journal of Pediatrics

Articles in Press

Current Issue

Volume 12 (2024)

Volume 11 (2023)

Volume 10 (2022)

Volume 9 (2021)

Volume 8 (2020)

Volume 7 (2019)

Volume 6 (2018)

Volume 5 (2017)

Volume 4 (2016)

Volume 3 (2015)

Volume 2 (2014)

Volume 1 (2013)

Author = Ali Ghasemi

Presentation of Sonographic Features of Pulmonary Invasive Fungal Disease in Six Children with Leukemia

Abstract

Effects of Nutritional variables in children with iron deficiency anemia

Abstract

Bilateral Spontaneous Hemothorax with PNET: a case report and review

Abstract

Hematopoietic Stem Cell Transplantation for Thalassemia

Abstract

Autologous Stem Cell in CHF(When is more effective?) Intracoronary Administration of Autologous Bone Marrow Stem Cell in Chronic Heart Failure

Abstract

General Anesthesia for Lumbar Puncture and Bone Marrow Aspiration /Biopsy in Children

Abstract

Evaluation of Therapeutic Effects of Autologous Bone Marrow Mesenchymal Stem Cells to Prevent the Progression of Chronic Nephropathy in Renal Transplant

Abstract